Metagenomi, Inc. (MGX)
- Previous Close
1.4500 - Open
1.4200 - Bid 1.3900 x 100
- Ask 1.4700 x 100
- Day's Range
1.3900 - 1.4800 - 52 Week Range
1.2300 - 5.6290 - Volume
581,585 - Avg. Volume
392,460 - Market Cap (intraday)
53.456M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8500 - Earnings Date Aug 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.80
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
metagenomi.coRecent News: MGX
View MorePerformance Overview: MGX
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGX
View MoreValuation Measures
Market Cap
53.46M
Enterprise Value
-128.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.17
Price/Book (mrq)
0.25
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-172.21%
Return on Assets (ttm)
-15.37%
Return on Equity (ttm)
-31.93%
Revenue (ttm)
45.26M
Net Income Avi to Common (ttm)
-77.95M
Diluted EPS (ttm)
-1.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
225.97M
Total Debt/Equity (mrq)
20.90%
Levered Free Cash Flow (ttm)
-68.74M